Home Journals Articles Updates About
CN
image
收藏切换
Progress of the development of anti-COVID-19 drugs
收藏切换
PDF
Li-ping LIN1, Fei TANG1, 2, Rui-an XU1, Xiu-ling CUI1, *
Acta Pharmaceutica Sinica | 2023, 58(1) : 39 - 51
Less
收藏切换
Acta Pharmaceutica Sinica | 2023, 58(1): 39-51
Progress of the development of anti-COVID-19 drugs
Full
Li-ping LIN1, Fei TANG1, 2, Rui-an XU1, Xiu-ling CUI1, *
Affiliations
  • 1. Engineering Research Center of the Ministry of Education for Molecular Drugs, Fujian Key Laboratory of Molecular Medicine, Fujian Key Laboratory of Precision Medicine and Molecular Diagnosis, Xiamen Key Laboratory of Marine and Genetic Drugs, College of Biomedicine, Huaqiao University, Xiamen 361021, China
  • 2. Xiamen Center for Disease Control and Prevention, Xiamen 361021, China
Published: 2023-01-12 doi: 10.16438/j.0513-4870.2022-0707
Outline
收藏切换

Since the outbreak of the novel coronavirus (SARS-CoV-2) disease COVID-19 (also known as 2019-nCoV) caused by SARS-CoV-2 in the end of 2019, it has spread rapidly in worldwide. Besides developing effective vaccines, it is urgent to develop safe and effective anti-SARS-CoV-2 drugs to fight this disease. Paxlovid, molnupiravir, sotrovimab and bebtelovimab are urgently authorized by FDA have been proved to be effective against Omicron. This manuscript mainly reviews the recent progress of effective inhibitors against the virus in the world, including receptor inhibitors, antibodies, natural product inhibitors, synthetic inhibitors and broad-spectrum antiviral drugs that are effective against other RNA viruses.

COVID-19  /  target  /  medication  /  drug repurposing  /  drug discovery
Li-ping LIN, Fei TANG, Rui-an XU, Xiu-ling CUI. Progress of the development of anti-COVID-19 drugs[J]. Acta Pharmaceutica Sinica, 2023 , 58 (1) : 39 -51 . DOI: 10.16438/j.0513-4870.2022-0707
Appendix
Less
Year 2023 volume 58 Issue 1
PDF
139
56
Cite this Article
BibTeX
Article Info
doi: 10.16438/j.0513-4870.2022-0707
  • Receive Date：2022-06-09
  • Online Date：2025-11-21
  • Published：2023-01-12
Article Data
Affiliations
History
  • Received：2022-06-09
  • Revised：2022-07-08
Funding
Affiliations
    1. Engineering Research Center of the Ministry of Education for Molecular Drugs, Fujian Key Laboratory of Molecular Medicine, Fujian Key Laboratory of Precision Medicine and Molecular Diagnosis, Xiamen Key Laboratory of Marine and Genetic Drugs, College of Biomedicine, Huaqiao University, Xiamen 361021, China
    2. Xiamen Center for Disease Control and Prevention, Xiamen 361021, China
References
Share
https://castjournals.cast.org.cn/joweb/yxxb/EN/10.16438/j.0513-4870.2022-0707
Share to
QR

Scan QR to access full text

Cite this article
BibTeX
Citations
表12种不同金属材料的力学参数
科
Family		 属数
Number of
genus		 种数
Number of
species		 占总种数比例
Percentage of
total species (%)		 属
Genus		 种数
Number of
species		 占总种数比例
Percentage of total
species (%)
鹅膏菌科Amanitaceae 2 11 5.26 鹅膏菌属 Amanita 10 4.78
小菇科 Mycenaceae 2 12 5.74 丝盖伞属 Inocybe 5 2.39
多孔菌科 Polyporaceae 8 14 6.70 蜡蘑属 Laccaria 5 2.39
红菇科 Russulaceae 3 23 11.00 小皮伞属 Marasmius 6 2.87
小菇属 Mycena 11 5.26
光柄菇属 Pluteus 5 2.39
红菇属 Russula 17 8.13
栓菌属 Trametes 5 2.39
关闭全屏
  • BibTeX
  • EndNote
  • RefWorks
  • TxT
Links
Articles
Latest Articles
Most Read
Collections
Updates
Events
News
Multimedia
About
About Us
Contact
No. 86 Xueyuan South Road, Haidian District, Beijing
100081
010-62199257
qkjq@cast.org.cn

Copyright © 2025 China Association for Science and Technology. All rights reserved. For all open access content, the relevant licensing terms apply.
Sponsored by the Office of the Leading Group for Cybersecurity and Informatization of CAST, and supported by Science and Technology Review Publishing House